The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Open Access
- 25 May 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Musculoskeletal Disorders
- Vol. 15 (1), 1-9
- https://doi.org/10.1186/1471-2474-15-178
Abstract
Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia. We performed a single centre retrospective review of 177 patients with multisystem autoimmune disease receiving rituximab between 2002 and 2010. The incidence, severity and complications of hypogammaglobulinaemia were investigated. Median rituximab dose was 6 g (1–20.2) and total follow-up was 8012 patient-months. At first rituximab, the proportion of patients with IgG <6 g/L was 13% and remained stable at 17% at 24 months and 14% at 60 months. Following rituximab, 61/177 patients (34%) had IgG <6 g/L for at least three consecutive months, of whom 7/177 (4%) had IgG <3 g/L. Low immunoglobulin levels were associated with higher glucocorticoid doses during follow up and there was a trend for median IgG levels to fall after ≥ 6 g rituximab. 45/115 (39%) with IgG ≥6 g/L versus 26/62 (42%) with IgG <6 g/L experienced severe infections (p = 0.750). 6/177 patients (3%) received intravenous immunoglobulin replacement therapy, all with IgG <5 g/L and recurrent infection. In multi-system autoimmune disease, prior cyclophosphamide exposure and glucocorticoid therapy but not cumulative rituximab dose was associated with an increased incidence of hypogammaglobulinaemia. Severe infections were common but were not associated with immunoglobulin levels. Repeat dose rituximab therapy appears safe with judicious monitoring.Keywords
This publication has 38 references indexed in Scilit:
- Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single centerArthritis & Rheumatism, 2012
- Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitisRheumatology, 2011
- Biological therapy for lupus nephritis—tribulations and trialsNature Reviews Rheumatology, 2010
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisNew England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2009
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998